BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64:S71-S83. [PMID: 27084039 DOI: 10.1016/j.jhep.2016.01.026] [Cited by in Crossref: 220] [Cited by in F6Publishing: 200] [Article Influence: 44.0] [Reference Citation Analysis]
Number Citing Articles
1 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? J Hepatol 2022;76:1249-62. [PMID: 35589248 DOI: 10.1016/j.jhep.2021.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Guang Y, Yuzhong L, Hui L. Establishment of an analysis model based on measurement of hepatitis B viral infection serum markers. BMC Infect Dis 2019;19:171. [PMID: 30777024 DOI: 10.1186/s12879-019-3813-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Burton AR, Maini MK. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. Immunol Rev 2021;299:108-17. [PMID: 33559128 DOI: 10.1111/imr.12953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. Hepatology 2021;74:55-71. [PMID: 33368377 DOI: 10.1002/hep.31695] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
6 Hong B, Wang L, Huang C, Hong X, Liu A, Li Q, Liu Q, Su L, Wang L, Wang C, Ying T. Decrease of Clone Diversity in IgM Repertoires of HBV Chronically Infected Individuals With High Level of Viral Replication. Front Microbiol 2020;11:615669. [PMID: 33519772 DOI: 10.3389/fmicb.2020.615669] [Reference Citation Analysis]
7 Paximadis M, Perez Patrigeon S, Rajasuriar R, Tatoud R, Scully E, Arbuthnot P. Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research. Journal of Virus Eradication 2019;5:234-44. [DOI: 10.1016/s2055-6640(20)30027-3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Ji L, Gao Q, Guo R, Zhang X, Zhou Z, Yu Z, Zhu X, Gao Y, Sun X, Gao Y, Li M. Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients. Journal of Immunology Research 2019;2019:1-10. [DOI: 10.1155/2019/8983903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 2019;156:325-337. [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
10 Andrisani O. Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma. Hepatoma Res 2021;7:12. [PMID: 33614973 DOI: 10.20517/2394-5079.2020.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhao W, Zhou X, Zhao G, Lin Q, Wang X, Yu X, Wang B. Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model. Hum Vaccin Immunother 2017;13:2872-82. [PMID: 28699816 DOI: 10.1080/21645515.2017.1344797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
12 Bertoletti A. T cell fitness in the liver: How can T cells keep it up? Journal of Hepatology 2016;64:1208-10. [DOI: 10.1016/j.jhep.2016.02.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol 2017;8:1142. [PMID: 28959264 DOI: 10.3389/fimmu.2017.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Corti D, Benigni F, Shouval D. Viral envelope-specific antibodies in chronic hepatitis B virus infection. Curr Opin Virol 2018;30:48-57. [PMID: 29738926 DOI: 10.1016/j.coviro.2018.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
15 Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology 2019; 157: 227-241. e7. [PMID: 30930022 DOI: 10.1053/j.gastro.2019.03.044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
16 Zoulim F. Inhibition of hepatitis B virus gene expression: A step towards functional cure. J Hepatol 2018;68:386-8. [PMID: 29217272 DOI: 10.1016/j.jhep.2017.11.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
17 Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
19 Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2021. [PMID: 34002067 DOI: 10.1038/s41577-021-00549-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
20 Jiang D, Chen C, Yan D, Zhang X, Liu X, Yan D, Cui D, Yang S. Exhausted phenotype of circulating CD8+ T cell subsets in hepatitis B virus carriers. BMC Immunol 2022;23:18. [PMID: 35443611 DOI: 10.1186/s12865-022-00488-2] [Reference Citation Analysis]
21 Zhou SN, Zhang N, Liu HH, Xia P, Zhang C, Song JW, Fan X, Shi M, Jin L, Zhang JY, Wang FS. Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B. Gastroenterol Rep (Oxf) 2021;9:49-58. [PMID: 33747526 DOI: 10.1093/gastro/goaa048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu N, Liu B, Zhang L, Li H, Chen Z, Luo A, Chen M, Peng M, Yin W, Ren H, Hu P. Recovery of circulating CD56dim NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. Int Immunopharmacol 2018;62:59-66. [PMID: 29990695 DOI: 10.1016/j.intimp.2018.06.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jansen DT, Dou Y, de Wilde JW, Woltman AM, Buschow SI. Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures. Clin Transl Immunology 2021;10:e1232. [PMID: 33489122 DOI: 10.1002/cti2.1232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
25 Höner zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, Deterding K, Port K, Mix C, Manns MP, Herrmann E, Wedemeyer H, Kraft ARM, Cornberg M. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. J Infect Dis 2016;214:1492-7. [DOI: 10.1093/infdis/jiw412] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 11.3] [Reference Citation Analysis]
26 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Du Y, Wu J, Liu J, Zheng X, Yang D, Lu M. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection. Front Immunol 2022;13:965018. [DOI: 10.3389/fimmu.2022.965018] [Reference Citation Analysis]
28 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Yan D, Yang J, Ji Z, Wang J, Lu X, Huang Y, Zhong C, Li L. Profiling T cell receptor β-chain in responders after immunization with recombinant hepatitis B vaccine. J Gene Med 2021;23:e3367. [PMID: 34048625 DOI: 10.1002/jgm.3367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Engle RE, De Battista D, Danoff EJ, Nguyen H, Chen Z, Lusso P, Purcell RH, Farci P. Distinct Cytokine Profiles Correlate with Disease Severity and Outcome in Longitudinal Studies of Acute Hepatitis B Virus and Hepatitis D Virus Infection in Chimpanzees. mBio 2020;11:e02580-20. [PMID: 33203756 DOI: 10.1128/mBio.02580-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Lin TC, Liu WC, Hsu YH, Lin JJ, Chiu YC, Chiu HC, Cheng PN, Chen CY, Chang TT, Wu IC. Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. J Clin Med 2019;8:E1892. [PMID: 31698809 DOI: 10.3390/jcm8111892] [Reference Citation Analysis]
32 Dou Y, Jansen DTSL, van den Bosch A, de Man RA, van Montfoort N, Araman C, van Kasteren SI, Zom GG, Krebber WJ, Melief CJM, Woltman AM, Buschow SI. Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients. Antiviral Res 2020;178:104746. [PMID: 32081741 DOI: 10.1016/j.antiviral.2020.104746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, Yu D, Han Y, Zhang D, Chen P, Zhang X, Yuan Z, Huang J, Zhang X. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep 2017;7:43446. [PMID: 28262670 DOI: 10.1038/srep43446] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
34 Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA, Schurich A, Swadling L, Gill US, Male V, Luong T, Gander A, Davidson BR, Kennedy PTF, Maini MK. IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med. 2017;214:1567-1580. [PMID: 28526759 DOI: 10.1084/jem.20162115] [Cited by in Crossref: 168] [Cited by in F6Publishing: 165] [Article Influence: 33.6] [Reference Citation Analysis]
35 Zheng J, Ou Z, Xu Y, Xia Z, Lin X, Jin S, Liu Y, Wu J. Hepatitis B virus-specific effector CD8+ T cells are an important determinant of disease prognosis: A meta-analysis. Vaccine 2019;37:2439-46. [PMID: 30935741 DOI: 10.1016/j.vaccine.2019.03.058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Bertoletti A, Le Bert N. Immunotherapy for Chronic Hepatitis B Virus Infection. Gut Liver 2018;12:497-507. [PMID: 29316747 DOI: 10.5009/gnl17233] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 18.7] [Reference Citation Analysis]
37 Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol 2019;10:2048. [PMID: 31507621 DOI: 10.3389/fimmu.2019.02048] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
38 van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
39 Hoogeveen RC, Dijkstra S, Bartsch LM, Drescher H, Aneja J, Robidoux MP, Cheney JA, Timm J, Gehring A, Fonseca de Sousa PS, Ximenez L, Peliganga LB, Pitts A, Blackburn FE, Boonstra A, Kim AY, Lewis-Ximenez LL, Lauer GM. Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen+ infection. J Hepatol 2022:S0168-8278(22)00366-X. [PMID: 35716846 DOI: 10.1016/j.jhep.2022.05.041] [Reference Citation Analysis]
40 Suresh M, Li B, Huang X, Korolowicz KE, Murreddu MG, Gudima SO, Menne S. Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects. Front Immunol 2021;12:745802. [PMID: 34671360 DOI: 10.3389/fimmu.2021.745802] [Reference Citation Analysis]
41 Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A. The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses 2020;12:E746. [PMID: 32664401 DOI: 10.3390/v12070746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Huang C, Ge T, Xia C, Zhu W, Xu L, Wang Y, Wu F, Liu F, Zheng M, Chen Z. Association of rs10204525 genotype GG and rs2227982 CC combination in programmed cell death 1 with hepatitis B virus infection risk. Medicine (Baltimore). 2019;98:e16972. [PMID: 31464942 DOI: 10.1097/md.0000000000016972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
44 Sellau J, Puengel T, Hoenow S, Groneberg M, Tacke F, Lotter H. Monocyte dysregulation: consequences for hepatic infections. Semin Immunopathol 2021. [PMID: 33829283 DOI: 10.1007/s00281-021-00852-1] [Reference Citation Analysis]
45 de Beijer MTA, Jansen DTSL, Dou Y, van Esch WJE, Mok JY, Maas MJP, Brasser G, de Man RA, Woltman AM, Buschow SI. Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength. J Virol 2020;94:e01663-19. [PMID: 31852786 DOI: 10.1128/JVI.01663-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wang Q, Pan W, Liu Y, Luo J, Zhu D, Lu Y, Feng X, Yang X, Dittmer U, Lu M, Yang D, Liu J. Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. Front Immunol 2018;9:219. [PMID: 29483916 DOI: 10.3389/fimmu.2018.00219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
47 Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783. [PMID: 32217150 DOI: 10.1016/j.antiviral.2020.104783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
49 Bourgine M, Crabe S, Lobaina Y, Guillen G, Aguilar JC, Michel ML. Nasal route favors the induction of CD4+ T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine. Antiviral Res 2018;153:23-32. [PMID: 29510155 DOI: 10.1016/j.antiviral.2018.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Alexopoulou A, Vasilieva L, Karayiannis P. New Approaches to the Treatment of Chronic Hepatitis B. J Clin Med 2020;9:E3187. [PMID: 33019573 DOI: 10.3390/jcm9103187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
51 Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses 2019;11:E778. [PMID: 31450544 DOI: 10.3390/v11090778] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
52 Joshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatol Commun. 2020;4:157-171. [PMID: 32025602 DOI: 10.1002/hep4.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
53 Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
54 Masrour-Roudsari J, Hasanjani-Roushan M, Yahyapour Y, Barari-Savadkoohi R, Bijani A, Sadeghi F, Mohammadnia-Afroozi M. HBS Ag seroclearance and seroconversion time in Patients with chronic hepatitis B Infection. Caspian J Intern Med 2020;11:205-10. [PMID: 32509250 DOI: 10.22088/cjim.11.2.205] [Reference Citation Analysis]
55 Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol 2018;3:192-202. [PMID: 29870733 DOI: 10.1016/S2468-1253(18)30007-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 12.5] [Reference Citation Analysis]
56 Masuta Y, Yamamoto T, Natsume-Kitatani Y, Kanuma T, Moriishi E, Kobiyama K, Mizuguchi K, Yasutomi Y, Ishii KJ. An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates. J Immunol 2018;200:2067-75. [PMID: 29431693 DOI: 10.4049/jimmunol.1701183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
58 Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, Ramakrishnan D, Pattabiraman D, Spurlock S, Chu R, Kang D, Mish M, Ramirez R, Li L, Li B, Ma S, Hung M, Voitenleitner C, Yon C, Suresh M, Menne S, Cote P, Delaney WE 4th, Mackman R, Fletcher SP. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B. Hepatology 2021;73:53-67. [PMID: 32246499 DOI: 10.1002/hep.31255] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
60 Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, d'Arminio Monforte A, Marchetti G, Milazzo L. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study. J Viral Hepat 2018;25:381-90. [PMID: 29091327 DOI: 10.1111/jvh.12820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
61 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
62 Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 2018;128:4573-87. [PMID: 30084841 DOI: 10.1172/JCI121957] [Cited by in Crossref: 101] [Cited by in F6Publishing: 64] [Article Influence: 25.3] [Reference Citation Analysis]
63 Liu W, Zheng X, Wang J, He Q, Li J, Zhang Z, Liu H. MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases. Lab Med 2021:lmaa110. [PMID: 33410459 DOI: 10.1093/labmed/lmaa110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Aono S, Tatsumi T, Yoshioka T, Tawara S, Nishio A, Onishi Y, Fukutomi K, Nakabori T, Kodama T, Shigekawa M, Hikita H, Sakamori R, Takahashi T, Suemizu H, Takehara T. Immunological responses against hepatitis B virus in human peripheral blood mononuclear cell-engrafted mice. Biochem Biophys Res Commun 2018;503:1457-64. [PMID: 30033102 DOI: 10.1016/j.bbrc.2018.07.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
65 Uhlving HH, Harritshøj LH, Christensen VB, Ifversen M. Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection. Pediatr Blood Cancer 2021;:e29208. [PMID: 34227723 DOI: 10.1002/pbc.29208] [Reference Citation Analysis]
66 Chen Z, Engle RE, Shen CH, Zhao H, Schuck PW, Danoff EJ, Nguyen H, Nishimura N, Bock KW, Moore IN, Kwong PD, Purcell RH, Govindarajan S, Farci P. Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans. PLoS Pathog 2020;16:e1008793. [PMID: 32866189 DOI: 10.1371/journal.ppat.1008793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Mondelli MU. Exosomes: multitask cargo carriers modulating innate immunity to viruses. Cell Mol Immunol 2017;14:476-7. [PMID: 27264688 DOI: 10.1038/cmi.2016.27] [Reference Citation Analysis]
68 Iannacone M, Andreata F, Guidotti LG. Immunological insights in the treatment of chronic hepatitis B. Curr Opin Immunol 2022;77:102207. [PMID: 35588690 DOI: 10.1016/j.coi.2022.102207] [Reference Citation Analysis]
69 Robbiani DF. Neutralizing hepatitis B. J Exp Med 2020;217:e20201261. [PMID: 32790869 DOI: 10.1084/jem.20201261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zahn T, Akhras S, Spengler C, Murra RO, Holzhauser T, Hildt E. A new approach for therapeutic vaccination against chronic HBV infections. Vaccine 2020;38:3105-20. [DOI: 10.1016/j.vaccine.2020.02.063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
71 Fu X, Lou H, Chen F, Gao X, Lin Z. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels. Clin Exp Med 2020;20:241-8. [PMID: 32052245 DOI: 10.1007/s10238-019-00603-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Shoukry NH, Walker CM. T cell responses during HBV and HCV infections: similar but not quite the same? Curr Opin Virol 2021;51:80-6. [PMID: 34619514 DOI: 10.1016/j.coviro.2021.08.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Loukachov V, van Dort KA, Jansen L, Reesink HW, Kootstra NA. Identification of a Novel HBV Encoded miRNA Using Next Generation Sequencing. Viruses 2022;14:1223. [DOI: 10.3390/v14061223] [Reference Citation Analysis]
74 Deng Q, Luo Y, Chang C, Wu H, Ding Y, Xiao R. The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review. Front Immunol 2019;10:856. [PMID: 31057561 DOI: 10.3389/fimmu.2019.00856] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
75 Lang J, Neumann-haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int 2019;13:113-24. [DOI: 10.1007/s12072-018-9912-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
76 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
77 de Almeida Pondé RA. Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure. Microbiol Immunol 2021. [PMID: 34528725 DOI: 10.1111/1348-0421.12943] [Reference Citation Analysis]
78 Vyas AK, Negi P, Patra S, Maras JS, Ramakrishna G, Sarin SK, Trehanpati N. Maternal Immunity Influences Vertical Transmission of Hepatitis B to Newborns. Hepatol Commun 2019;3:795-811. [PMID: 31168514 DOI: 10.1002/hep4.1351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Connolly R, Denton MD, Humphreys H, McLoughlin RM. Would hemodialysis patients benefit from a Staphylococcus aureus vaccine? Kidney Int 2019;95:518-25. [PMID: 30691691 DOI: 10.1016/j.kint.2018.10.023] [Reference Citation Analysis]
80 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
81 Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Reference Citation Analysis]
82 Ingiliz P, Canbay A. Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients. Aliment Pharmacol Ther 2018;47:1551-2. [PMID: 29878428 DOI: 10.1111/apt.14649] [Reference Citation Analysis]
83 Zhang ZQ, Shi BS, Lu W, Huang D, Wang YB, Feng YL. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J Virol Methods 2021;296:114226. [PMID: 34217779 DOI: 10.1016/j.jviromet.2021.114226] [Reference Citation Analysis]
84 Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 210] [Cited by in F6Publishing: 142] [Article Influence: 70.0] [Reference Citation Analysis]
85 Giadans CG, Ríos DA, Ameigeiras B, Pietrantonio AM, Lucatelli NL, Haddad L, Mullen E, Heinrich F, De Matteo E, Flichman D, Valva P, Preciado MV. Chronic hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage. J Viral Hepat 2019;26:727-37. [PMID: 30739377 DOI: 10.1111/jvh.13078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Chua CG, Mehrotra A, Mazzulli T, Wong DK, Feld JJ, Janssen HLA, Gehring AJ. Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. Sci Rep 2020;10:11344. [PMID: 32647116 DOI: 10.1038/s41598-020-68226-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 de Groen RA, Hou J, van Oord GW, Groothuismink ZM, van der Heide M, de Knegt RJ, Boonstra A. NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. Antiviral Research 2017;140:18-24. [DOI: 10.1016/j.antiviral.2017.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
88 Wang T, Qi J, Li H, Chen L, Liu S, Shen C. Human leukocyte antigen class I association with occult hepatitis B virus infection in the Shaanxi Han group: Analysis at the haplotype level. J Gene Med 2022;24:e3393. [PMID: 34643983 DOI: 10.1002/jgm.3393] [Reference Citation Analysis]
89 Ho E, Van Hees S, Goethals S, Smits E, Huizing M, Francque S, De Winter B, Michielsen P, Vanwolleghem T. Biobanking for Viral Hepatitis Research. Front Med (Lausanne) 2019;6:183. [PMID: 31482092 DOI: 10.3389/fmed.2019.00183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
90 Chen L, Zhang Y, Zhang S, Chen Y, Shu X, Lai J, Cao H, Lian Y, Stamataki Z, Huang Y. A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion. Arch Virol 2019;164:483-95. [PMID: 30415392 DOI: 10.1007/s00705-018-4095-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
91 Fisicaro P, Rossi M, Vecchi A, Acerbi G, Barili V, Laccabue D, Montali I, Zecca A, Penna A, Missale G, Ferrari C, Boni C. The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. Int J Mol Sci 2019;20:E5080. [PMID: 31614928 DOI: 10.3390/ijms20205080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
92 Hong B, Liu Q, Li Q, Su L, Wang L. Lower Somatic Mutation Levels in the λ Light-Chain Repertoires with Chronic HBV Infection. Evid Based Complement Alternat Med 2021;2021:5525369. [PMID: 34239579 DOI: 10.1155/2021/5525369] [Reference Citation Analysis]
93 Cheng Y, Gunasegaran B, Singh HD, Dutertre C, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BK, Chow PK, Chan JK, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021;54:1825-1840.e7. [DOI: 10.1016/j.immuni.2021.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Burwitz BJ, Hashiguchi PK, Mansouri M, Meyer C, Gilbride RM, Biswas S, Womack JL, Reed JS, Wu HL, Axthelm MK, Hansen SG, Picker LJ, Früh K, Sacha JB. MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes. J Immunol 2020;204:2169-76. [PMID: 32161099 DOI: 10.4049/jimmunol.1900795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
95 Wang Y, Mei Y, Ao Z, Chen Y, Jiang Y, Chen X, Qi R, Fu B, Tang J, Fang M, You M, Zhang T, Yuan Q, Luo W, Xia N. A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Du Y, Anastasiou OE, Strunz B, Scheuten J, Bremer B, Kraft A, Kleinsimglinhaus K, Todt D, Broering R, Hardtke-Wolenski M, Wu J, Yang D, Dittmer U, Lu M, Cornberg M, Björkström NK, Khera T, Wedemeyer H. The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. Liver Int 2021;41:2046-58. [PMID: 33794040 DOI: 10.1111/liv.14885] [Reference Citation Analysis]
97 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
98 Gu Y, Li X, Gu L, Lian Y, Wang K, Chen Y, Lai J, Mei Y, Liu J, Huang Z, Zhang M, Chen L, Huang Y. An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B. Aging (Albany NY) 2020;12:26063-79. [PMID: 33401245 DOI: 10.18632/aging.202274] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Cheng Y, Zhu YO, Becht E, Aw P, Chen J, Poidinger M, de Sessions PF, Hibberd ML, Bertoletti A, Lim SG, Newell EW. Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection. Sci Immunol 2019;4:eaau6905. [DOI: 10.1126/sciimmunol.aau6905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
100 Sun Y, Yu M, Qu M, Ma Y, Zheng D, Yue Y, Guo S, Tang L, Li G, Zheng W, Wang M, Guo D, Li C. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion. Am J Physiol Gastrointest Liver Physiol 2020;318:G162-73. [PMID: 31604033 DOI: 10.1152/ajpgi.00197.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
101 Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc 2021;120:1676-85. [PMID: 33339708 DOI: 10.1016/j.jfma.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Zhong S, Liu Z, Zhou Y, Zhang T, Fu X, Guo L, Gu S, Tang L, Hou J, Li Y. Longitudinal mapping of hepatitis B vaccine-induced B-cell linear epitopes in healthy individuals. J Med Virol 2022. [PMID: 35676468 DOI: 10.1002/jmv.27926] [Reference Citation Analysis]
103 Ye J, Xie P, Zhou Z, Sun Y, Wang F, You Y, Teng J, Yang C, Zhang X, Han Y. Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted. Front Med (Lausanne) 2022;9:814423. [PMID: 35223909 DOI: 10.3389/fmed.2022.814423] [Reference Citation Analysis]
104 Neumann-Haefelin C, Thimme R. Entering the spotlight: hepatitis B surface antigen-specific B cells. J Clin Invest 2018;128:4257-9. [PMID: 30222139 DOI: 10.1172/JCI124098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
105 Zhang J, Wang Z, Yang W, Zhang J, Wang Y, Liu J. Re: "CXCR5+ CD8+ T Cells Indirectly Offer B Cell Help and Are Inversely Correlated with Viral Load in Chronic Hepatitis B Infection" by Jiang et al. (DNA Cell Biol 2017;36, 321-327). DNA Cell Biol 2019;38:107-12. [PMID: 30427730 DOI: 10.1089/dna.2018.4278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Koffas A, Mak L, Gill US, Kennedy PTF. Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? Viruses 2022;14:900. [DOI: 10.3390/v14050900] [Reference Citation Analysis]
107 Zhao F, Xie X, Tan X, Yu H, Tian M, Lv H, Qin C, Qi J, Zhu Q. The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis. Front Immunol 2021;12:691766. [PMID: 34456908 DOI: 10.3389/fimmu.2021.691766] [Reference Citation Analysis]
108 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020; 26(9): 883-903 [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
110 Li T, Gao N, Cui W, Zhao L, Du J, Shi X, Zhu J, Qiao Z, Guo S, Pan L. The role of CD8+ Granzyme B+ T cells in the pathogenesis of Takayasu's arteritis. Clin Rheumatol 2021. [PMID: 34494213 DOI: 10.1007/s10067-021-05903-4] [Reference Citation Analysis]
111 Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603. [PMID: 30091725 DOI: 10.1172/jci121960] [Cited by in Crossref: 103] [Cited by in F6Publishing: 62] [Article Influence: 25.8] [Reference Citation Analysis]
112 Ma L, Sun X, Kong X, Gao Y. B cell dysfunction in chronic hepatitis B virus infection. Liver Research 2021;5:11-5. [DOI: 10.1016/j.livres.2020.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Bertoletti A. The challenges to adopt immunological biomarkers in the management of Chronic HBV infection. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.028] [Reference Citation Analysis]
114 Zhang G, Li X, Liu L, Li J, Chen Q, Huang S, Li Y, Wan X. Vaccination with a DNA vaccine encoding CD317-targeting HBs antigen elicits enhanced immunity in mice. Biochem Biophys Res Commun 2018;504:865-70. [PMID: 30219230 DOI: 10.1016/j.bbrc.2018.09.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
115 Zou X, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2021;19:597-603. [PMID: 32553907 DOI: 10.1016/j.cgh.2020.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
116 Talele TT. Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon. J Med Chem 2020;63:13291-315. [PMID: 32805118 DOI: 10.1021/acs.jmedchem.0c00829] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
117 Jin J, Xu H, Wu R, Gao N, Wu N, Li S, Niu J. Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection. J Cell Mol Med 2019;23:7474-89. [PMID: 31565863 DOI: 10.1111/jcmm.14616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
118 Salimi Alizei E, Hofmann M, Thimme R, Neumann-Haefelin C. Mutational escape from cellular immunity in viral hepatitis: variations on a theme. Curr Opin Virol 2021;50:110-8. [PMID: 34454351 DOI: 10.1016/j.coviro.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Chang L, Wang L, Ling N, Peng H, Chen M. Increase in liver γδ T cells with concurrent augmentation of IFN-β production during the early stages of a mouse model of acute experimental hepatitis B virus infection. Exp Ther Med 2020;19:67-78. [PMID: 31853274 DOI: 10.3892/etm.2019.8197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Qu M, Yuan X, Liu D, Ma Y, Zhu J, Cui J, Yu M, Li C, Guo D. Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Immune-Mediated Liver Injury and Compromise Virus Control During Acute Hepatitis B Virus Infection in Mice. Stem Cells Dev 2017;26:818-27. [PMID: 28318408 DOI: 10.1089/scd.2016.0348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
121 van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
122 Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol 2020;72:34-44. [PMID: 31348999 DOI: 10.1016/j.jhep.2019.07.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
123 Ning L, Huang X, Xu Y, Yang G, Yang J, Fu Q, Zhang Q, Liu H, Wu X, Wang Z, Luo K. Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients. J Interferon Cytokine Res 2019;39:740-51. [PMID: 31329012 DOI: 10.1089/jir.2019.0042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Molyvdas A, Georgopoulou U, Lazaridis N, Hytiroglou P, Dimitriadis A, Foka P, Vassiliadis T, Loli G, Phillipidis A, Zebekakis P, Germenis AE, Speletas M, Germanidis G. The role of the NLRP3 inflammasome and the activation of IL-1β in the pathogenesis of chronic viral hepatic inflammation. Cytokine 2018;110:389-96. [PMID: 29803661 DOI: 10.1016/j.cyto.2018.04.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
125 Garssen J, Jo J; 1 Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands, 2 Department of Immunology, Nutricia Research, Utrecht, the Netherlands, 3 Department of Immunology, Nutricia Research, Singapore. . AIMS Allergy and Immunology 2017;1:43-9. [DOI: 10.3934/allergy.2017.1.43] [Reference Citation Analysis]
126 Durantel D, Kusters I, Louis J, Manel N, Ottenhoff THM, Picot V, Saaadatian-Elahi M. Mechanisms behind TB, HBV, and HIV chronic infections. Infect Genet Evol 2017;55:142-50. [PMID: 28919545 DOI: 10.1016/j.meegid.2017.09.008] [Reference Citation Analysis]
127 Gaur P, Cebula M, Riehn M, Hillebrand U, Hauser H, Wirth D. Diet induced obesity has an influence on intrahepatic T cell responses. Metabolism 2017;69:171-6. [DOI: 10.1016/j.metabol.2017.01.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
128 Mackman RL, Mish M, Chin G, Perry JK, Appleby T, Aktoudianakis V, Metobo S, Pyun P, Niu C, Daffis S, Yu H, Zheng J, Villasenor AG, Zablocki J, Chamberlain J, Jin H, Lee G, Suekawa-pirrone K, Santos R, Delaney WE, Fletcher SP. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem 2020;63:10188-203. [DOI: 10.1021/acs.jmedchem.0c00100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
129 Han JW, Shin EC. Liver-Resident Memory CD8+ T Cells: Possible Roles in Chronic HBV Infection. Int J Mol Sci 2020;22:E283. [PMID: 33396596 DOI: 10.3390/ijms22010283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Acerbi G, Montali I, Ferrigno GD, Barili V, Schivazappa S, Alfieri A, Laccabue D, Loglio A, Borghi M, Massari M, Rossi M, Vecchi A, Penna A, Boni C, Missale G, Lampertico P, Del Rio D, Ferrari C, Fisicaro P. Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. J Hepatol 2021;74:783-93. [PMID: 33188902 DOI: 10.1016/j.jhep.2020.10.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Krieger J, Stifter K, Riedl P, Schirmbeck R. Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination. Sci Rep 2018;8:14660. [PMID: 30279478 DOI: 10.1038/s41598-018-32971-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
132 Ma H, Lim TH, Leerapun A, Weltman M, Jia J, Lim YS, Tangkijvanich P, Sukeepaisarnjaroen W, Ji Y, Le Bert N, Li D, Zhang Y, Hamatake R, Tan N, Li C, Strasser SI, Ding H, Yoon JH, Stace NH, Ahmed T, Anderson DE, Yan L, Bertoletti A, Zhu Q, Yuen MF. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep 2021;3:100361. [PMID: 34661089 DOI: 10.1016/j.jhepr.2021.100361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
133 Schuch A, Zecher BF, Müller PA, Correia MP, Daul F, Rennert C, Tauber C, Schlitt K, Boettler T, Neumann-Haefelin C, Hengel H, Pircher H, Cerwenka A, Thimme R, Hofmann M. NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. J Hepatol 2019;70:351-60. [PMID: 30342116 DOI: 10.1016/j.jhep.2018.10.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
134 Wu J, Han M, Li J, Yang X, Yang D. Immunopathogenesis of HBV Infection. In: Tang H, editor. Hepatitis B Virus Infection. Singapore: Springer; 2020. pp. 71-107. [DOI: 10.1007/978-981-13-9151-4_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
136 Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018;24:108-113. [PMID: 29353469 DOI: 10.3350/cmh.2017.0068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
137 Hofmann M, Thimme R. Kill, control, or escape: Immune responses in viral hepatitis. Clin Liver Dis (Hoboken) 2016;8:79-82. [PMID: 31041069 DOI: 10.1002/cld.576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Xu Z, Lin JZ, Zeng YF, Yang XH, Wu ZB, Hu ZX, Zhao QY, Liu J, Gao ZL. Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure. J Med Virol 2021;93:4966-74. [PMID: 33913556 DOI: 10.1002/jmv.27041] [Reference Citation Analysis]
139 Hofmann M, Thimme R. Hepatitis B vaccine and NK cells: a new player in memory. Gut 2021;70:229-30. [PMID: 32669288 DOI: 10.1136/gutjnl-2020-321151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 2020;69:343-54. [PMID: 30926653 DOI: 10.1136/gutjnl-2018-317725] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
141 Cheng G, Yuan X, Wang F, Sun Q, Xin Q, Li K, Sun C, Lin Z, Luan Y, Xu Y, Li P, Kong F, Xu D. Association Between the Telomerase rs2736098_TT Genotype and a Lower Risk of Chronic Hepatitis B and Cirrhosis in Chinese Males. Clin Transl Gastroenterol 2017;8:e79. [PMID: 28300824 DOI: 10.1038/ctg.2017.9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
142 Gu Y, Lian Y, Gu L, Chen L, Li X, Zhou L, Huang Y, Wang J, Huang Y. Correlations between cytokines produced by T cells and clinical-virological characteristics in untreated chronic hepatitis B patients. BMC Infect Dis 2019;19:216. [PMID: 30832595 DOI: 10.1186/s12879-019-3853-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
143 Tseng TC, Huang LR. Immunopathogenesis of Hepatitis B Virus. J Infect Dis. 2017;216:S765-S770. [PMID: 29156047 DOI: 10.1093/infdis/jix356] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
144 Heim K, Neumann-Haefelin C, Thimme R, Hofmann M. Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. Front Immunol 2019;10:2240. [PMID: 31620140 DOI: 10.3389/fimmu.2019.02240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
145 Suresh M, Czerwinski S, Murreddu MG, Kallakury BV, Ramesh A, Gudima SO, Menne S. Innate and adaptive immunity associated with resolution of acute woodchuck hepatitis virus infection in adult woodchucks. PLoS Pathog. 2019;15:e1008248. [PMID: 31869393 DOI: 10.1371/journal.ppat.1008248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
146 Levrero M, Subic M, Villeret F, Zoulim F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology 2018;30:80-9. [DOI: 10.1016/j.coviro.2018.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
147 Bocharov G, Meyerhans A, Bessonov N, Trofimchuk S, Volpert V. Spatiotemporal Dynamics of Virus Infection Spreading in Tissues. PLoS One 2016;11:e0168576. [PMID: 27997613 DOI: 10.1371/journal.pone.0168576] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
148 Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9. [PMID: 28335554 DOI: 10.3390/v9030056] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 24.0] [Reference Citation Analysis]
149 Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, Vesin B, Lorin V, Hieu T, Stauffer A, Fiquet O, Dimitrov JD, Michel ML, Ungeheuer MN, Sureau C, Pol S, Di Santo JP, Strick-Marchand H, Pelletier N, Mouquet H. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med 2020;217:e20200840. [PMID: 32579155 DOI: 10.1084/jem.20200840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
150 Liu T, Wan Z, Peng S, Wang Y, Chen H, Li X, Du Y. Genetic variations in LTA gene and PDCD1 gene and intrauterine infection of hepatitis B virus: a case-control study in China. Amino Acids 2018;50:877-83. [PMID: 29786123 DOI: 10.1007/s00726-018-2568-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Wei X, Wang JP, Hao CQ, Yang XF, Wang LX, Huang CX, Bai XF, Lian JQ, Zhang Y. Notch Signaling Contributes to Liver Inflammation by Regulation of Interleukin-22-Producing Cells in Hepatitis B Virus Infection. Front Cell Infect Microbiol. 2016;6:132. [PMID: 27800305 DOI: 10.3389/fcimb.2016.00132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
152 Bertoletti A, Tan AT, Le Bert N. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology 2021;2:iqab006. [DOI: 10.1093/oxfimm/iqab006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
153 Gehring AJ. New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. Best Practice & Research Clinical Gastroenterology 2017;31:337-45. [DOI: 10.1016/j.bpg.2017.05.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
154 Beretta M, Mouquet H. Advances in human monoclonal antibody therapy for HBV infection. Curr Opin Virol 2022;53:101205. [PMID: 35123237 DOI: 10.1016/j.coviro.2022.101205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Gu S, Fu X, Ye G, Chen C, Li X, Zhong S, Tang L, Chen H, Jiang D, Hou J, Li Y. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. Front Immunol 2021;12:649197. [PMID: 34234772 DOI: 10.3389/fimmu.2021.649197] [Reference Citation Analysis]
156 Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients. J Viral Hepat 2017;24 Suppl 1:66-74. [PMID: 29082648 DOI: 10.1111/jvh.12791] [Reference Citation Analysis]
157 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Lian YF, Xu Y, Gu YR, Bi YH, Liao CH, Zhao MX, Liao XL, Wang ZH, Wu HK, Huang YH. Distinct T-cell receptor profiles associated with hepatitis B e antigen seroconversion during entecavir treatment. Liver Int. 2020;40:2672-2684. [PMID: 32564486 DOI: 10.1111/liv.14566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Ganesan M, Mathews S, Makarov E, Petrosyan A, Kharbanda KK, Kidambi S, Poluektova LY, Casey CA, Osna NA. Acetaldehyde suppresses HBV-MHC class I complex presentation on hepatocytes via induction of ER stress and Golgi fragmentation. Am J Physiol Gastrointest Liver Physiol 2020;319:G432-42. [PMID: 32755306 DOI: 10.1152/ajpgi.00109.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX, Tan AT, Kennedy PT, Maini M, Urban S, Bertoletti A. Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. J Virol. 2019;93(4). [PMID: 30518652 DOI: 10.1128/jvi.01457-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
161 Bertoletti A, Kennedy PTF. HBV antiviral immunity: not all CD8 T cells are born equal. Gut 2019;68:770-3. [PMID: 30700541 DOI: 10.1136/gutjnl-2018-317959] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
162 Xiong S, Zhu D, Liang B, Li M, Pan W, He J, Wang H, Sutter K, Dittmer U, Lu M, Liu D, Yang D, Liu J, Zheng X. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine 2021;69:103464. [PMID: 34233260 DOI: 10.1016/j.ebiom.2021.103464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Faure-Dupuy S, Lucifora J, Durantel D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. Viruses 2017;9:E95. [PMID: 28452930 DOI: 10.3390/v9050095] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
164 Jin X, Yan ZH, Lu L, Lu S, Zhang G, Lin W. Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:759292. [PMID: 34782855 DOI: 10.3389/fmed.2021.759292] [Reference Citation Analysis]
165 Su Z, Chen J, Zhang J, An Y, Liao Y, Wu X, Tao C, Wang L, Cai B, Cui D. Circulating IL-1β, IL-17, and IP-10 as Potential Predictors of Hepatitis B Virus Infection Prognosis. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/5202898] [Reference Citation Analysis]
166 Gu S, Lv L, Lin X, Li X, Dai J, Zhang J, Kong R, Xie W, Li J. Using structural analysis to explore the role of hepatitis B virus mutations in immune escape from liver cancer in Chinese, European and American populations. J Biomol Struct Dyn 2020;:1-11. [PMID: 33030111 DOI: 10.1080/07391102.2020.1830852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
168 Menzo S, Minosse C, Vincenti D, Vincenzi L, Iacomi F, Zaccaro P, D'Offizi G, Capobianchi MR. Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment. Genes (Basel) 2018;9:E293. [PMID: 29895748 DOI: 10.3390/genes9060293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
169 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
170 Broquetas T, Hernandez J, Garcia-retortillo M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Garrido E, Mico M, Bessa X, Carrión JA. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2021.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
171 Gu S, Liu Z, Lin L, Zhong S, Ma Y, Li X, Ye G, Wen C, Li Y, Tang L. Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array. Front Immunol 2021;12:767000. [PMID: 34721439 DOI: 10.3389/fimmu.2021.767000] [Reference Citation Analysis]
172 Boeijen LL, Hoogeveen RC, Boonstra A, Lauer GM. Hepatitis B virus infection and the immune response: The big questions. Best Pract Res Clin Gastroenterol. 2017;31:265-272. [PMID: 28774408 DOI: 10.1016/j.bpg.2017.05.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
173 Wedemeyer H. The widespread rarity of HBsAg loss in chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:190-2. [PMID: 30679108 DOI: 10.1016/S2468-1253(18)30384-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Buschow SI, Biesta PJ, Groothuismink ZMA, Erler NS, Vanwolleghem T, Ho E, Najera I, Ait-Goughoulte M, de Knegt RJ, Boonstra A, Woltman AM. TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands. Antiviral Res 2018;157:27-37. [PMID: 29964062 DOI: 10.1016/j.antiviral.2018.06.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
175 Fisicaro P, Boni C, Barili V, Laccabue D, Ferrari C. Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. Curr Opin Virol. 2018;30:1-8. [PMID: 29414066 DOI: 10.1016/j.coviro.2018.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
176 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
177 Chen C, Jiang X, Liu X, Guo L, Wang W, Gu S, Wen C, Yi X, Tang L, Li Y. Identification of the association between HBcAg-specific T cell and viral control in chronic HBV infection using a cultured ELISPOT assay. J Leukoc Biol 2021;109:455-65. [PMID: 32620046 DOI: 10.1002/JLB.5MA0620-023RR] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Fang Z, Yu X, Tong S, Lu C, Huang Y, Chen L, Yuan Z, Zhang Y. Serum ERK1/2 proteins fluctuating with HBV infection report frequency of viral-specific CD8+ T cells and predict IFNα therapeutic effect in chronic hepatitis B patients. Clin Immunol 2020;219:108570. [PMID: 32791312 DOI: 10.1016/j.clim.2020.108570] [Reference Citation Analysis]
179 Ferrari C, Boni C, Rossi M, Vecchi A, Barili V, Laccabue D, Fisicaro P, Missale G. T cell regulation in HBV-related chronic liver disease. Journal of Hepatology 2017;66:1096-8. [DOI: 10.1016/j.jhep.2016.10.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
180 Hasanpourghadi M, Novikov M, Newman D, Xiang Z, Zhou XY, Magowan C, Ertl HCJ. Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infection. Virol J 2021;18:242. [PMID: 34876153 DOI: 10.1186/s12985-021-01712-y] [Reference Citation Analysis]
181 Menne S, Wildum S, Steiner G, Suresh M, Korolowicz K, Balarezo M, Yon C, Murreddu M, Hong X, Kallakury BV, Tucker R, Yang S, Young JAT, Javanbakht H. Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus. Hepatol Commun 2020;4:916-31. [PMID: 32490326 DOI: 10.1002/hep4.1502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
182 Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol 2020;66:35-41. [PMID: 32361634 DOI: 10.1016/j.coi.2020.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
183 Zhan Q, Xu JH, Yu YY, Lo KK E, Felicianna, El-Nezami H, Zeng Z. Human immune repertoire in hepatitis B virus infection. World J Gastroenterol 2021; 27(25): 3790-3801 [PMID: 34321844 DOI: 10.3748/wjg.v27.i25.3790] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
184 Yip TC, Wong GL, Wong VW. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Clin Mol Hepatol 2021;27:273-7. [PMID: 33517606 DOI: 10.3350/cmh.2021.0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Yang S, Shen Z, Kang Y, Sun L, Viswanathan U, Guo H, Zhou T, Dai X, Chang J, Zhang J, Guo JT. A putative amphipathic alpha helix in hepatitis B virus small envelope protein plays a critical role in the morphogenesis of subviral particles. J Virol 2021:JVI. [PMID: 33536177 DOI: 10.1128/JVI.02399-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Gu Y, Chen L, Lian Y, Gu L, Chen Y, Bi Y, Huang Z, Huang Y, Hu B, Huang Y. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naïve chronic hepatitis B patients. J Med Virol 2020;92:317-28. [PMID: 31642539 DOI: 10.1002/jmv.25612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
188 Zhu W, Liu H, Zhang X. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection. ACS Infect Dis 2019;5:703-12. [PMID: 30907080 DOI: 10.1021/acsinfecdis.8b00297] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
189 Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
190 Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol 2016;30:93-105. [PMID: 27570126 DOI: 10.1016/j.coph.2016.07.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
191 Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hansi NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT, Bertoletti A. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018;128:668-681. [PMID: 29309050 DOI: 10.1172/jci92812] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 21.3] [Reference Citation Analysis]
192 Barili V, Boni C, Rossi M, Vecchi A, Zecca A, Penna A, Missale G, Ferrari C, Fisicaro P. Metabolic regulation of the HBV-specific T cell function. Antiviral Res 2021;185:104989. [PMID: 33248194 DOI: 10.1016/j.antiviral.2020.104989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. J Hepatol 2020;73:52-61. [PMID: 32061650 DOI: 10.1016/j.jhep.2020.01.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
194 Zhu F, Zhang Q, Zhang Q, Zhang D. Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis. Microb Pathog 2020;139:103912. [PMID: 31816402 DOI: 10.1016/j.micpath.2019.103912] [Reference Citation Analysis]
195 Chakrabarty G, Bruce M, Horner M, Wang B, Agarwal K, Carey I. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients? J Viral Hepat 2018;25:80-7. [PMID: 28710798 DOI: 10.1111/jvh.12756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900-907. [PMID: 31306680 DOI: 10.1016/j.jhep.2019.06.028] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 25.3] [Reference Citation Analysis]
197 Chen Z, Diaz G, Pollicino T, Zhao H, Engle RE, Schuck P, Shen CH, Zamboni F, Long Z, Kabat J, De Battista D, Bock KW, Moore IN, Wollenberg K, Soto C, Govindarajan S, Kwong PD, Kleiner DE, Purcell RH, Farci P. Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. Proc Natl Acad Sci USA. 2018;115:E11369-E11378. [PMID: 30420516 DOI: 10.1073/pnas.1809028115] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
198 Publicover J, Gaggar A, Jespersen JM, Halac U, Johnson AJ, Goodsell A, Avanesyan L, Nishimura SL, Holdorf M, Mansfield KG, Judge JB, Koshti A, Croft M, Wakil AE, Rosenthal P, Pai E, Cooper S, Baron JL. An OX40/OX40L interaction directs successful immunity to hepatitis B virus. Sci Transl Med. 2018;10. [PMID: 29563320 DOI: 10.1126/scitranslmed.aah5766] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
199 Cova L. Present and future DNA vaccines for chronic hepatitis B treatment. Expert Opinion on Biological Therapy 2016;17:185-95. [DOI: 10.1080/14712598.2017.1265940] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
200 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
201 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
202 Lu C, Chen H, Wang C, Yang F, Li J, Liu H, Chen G. An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation. Front Immunol 2021;12:798683. [PMID: 35154075 DOI: 10.3389/fimmu.2021.798683] [Reference Citation Analysis]
203 Yang S, Zeng W, Zhang J, Lu F, Chang J, Guo JT. Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary? Emerg Microbes Infect 2021;10:1545-54. [PMID: 34227927 DOI: 10.1080/22221751.2021.1952851] [Reference Citation Analysis]
204 Harroudi S, Meskaf A, Allali K. Modelling the Adaptive Immune Response in HBV Infection Model with HBV DNA-Containing Capsids. Differ Equ Dyn Syst. [DOI: 10.1007/s12591-020-00549-1] [Reference Citation Analysis]
205 Shi B, Wu Y, Wang C, Li X, Yu F, Wang B, Yang Z, Li J, Liang M, Wen Y, Ying T, Yuan Z. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine 2019;49:247-57. [PMID: 31680000 DOI: 10.1016/j.ebiom.2019.10.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Bunse T, Kosinska AD, Michler T, Protzer U. PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B. Biomolecules 2022;12:470. [DOI: 10.3390/biom12030470] [Reference Citation Analysis]
207 Fisicaro P, Barili V, Rossi M, Montali I, Vecchi A, Acerbi G, Laccabue D, Zecca A, Penna A, Missale G, Ferrari C, Boni C. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Front Immunol. 2020;11:849. [PMID: 32477347 DOI: 10.3389/fimmu.2020.00849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
208 Li Y, Yin S, Issa R, Tong X, Wang G, Xia J, Huang R, Chen G, Weng D, Chen C, Wu C, Chen Y. B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection. J Clin Transl Hepatol 2021;9:592-7. [PMID: 34447690 DOI: 10.14218/JCTH.2021.00051] [Reference Citation Analysis]
209 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
210 Zheng M, Tian Z. Liver-Mediated Adaptive Immune Tolerance. Front Immunol 2019;10:2525. [PMID: 31787967 DOI: 10.3389/fimmu.2019.02525] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
211 Xie X, Luo J, Zhu D, Zhou W, Yang X, Feng X, Lu M, Zheng X, Dittmer U, Yang D, Liu J. HBeAg Is Indispensable for Inducing Liver Sinusoidal Endothelial Cell Activation by Hepatitis B Virus. Front Cell Infect Microbiol 2022;12:797915. [DOI: 10.3389/fcimb.2022.797915] [Reference Citation Analysis]
212 Hao X, Chen Y, Bai L, Wei H, Sun R, Tian Z. HBsAg-specific CD8+ T cells as an indispensable trigger to induce murine hepatocellular carcinoma. Cell Mol Immunol 2021;18:128-37. [PMID: 31767976 DOI: 10.1038/s41423-019-0330-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
213 Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, Bertoletti A, Dandri M. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest 2017;127:3177-88. [PMID: 28737510 DOI: 10.1172/JCI93024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
214 Bertoletti A, Tan AT, Koh S. T-cell therapy for chronic viral hepatitis. Cytotherapy 2017;19:1317-24. [DOI: 10.1016/j.jcyt.2017.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
215 Dusheiko G. Current and future directions of management of hepatitis B: steps toward a cure. Future Virology 2018;13:189-209. [DOI: 10.2217/fvl-2017-0103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Liu B, Gao W, Zhang L, Wang J, Chen M, Peng M, Ren H, Hu P. Th17/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B. Int Immunopharmacol 2017;46:48-55. [PMID: 28259000 DOI: 10.1016/j.intimp.2017.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
217 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
219 Tandoh KZ, Quaye O. Genetic associations in chronic hepatitis B infection: toward developing polygenic risk scores. Future Microbiol 2022. [PMID: 35332782 DOI: 10.2217/fmb-2021-0176] [Reference Citation Analysis]
220 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
221 Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C. TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Gastroenterology 2018;154:1764-1777.e7. [DOI: 10.1053/j.gastro.2018.01.030] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 15.8] [Reference Citation Analysis]
222 Caviglia GP. Role of immunoglobulin indexes in patients with chronic hepatitis B. Minerva Med 2020;111:382-3. [PMID: 32700865 DOI: 10.23736/S0026-4806.20.06787-7] [Reference Citation Analysis]
223 Lumley SF, McNaughton AL, Klenerman P, Lythgoe KA, Matthews PC. Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Front Immunol 2018;9:1561. [PMID: 30061882 DOI: 10.3389/fimmu.2018.01561] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
224 Zhu B, Zhu Z, Wang J, Huang S, Li F, Wang L, Liu Y, Yan Q, Zhou S, Lu M, Yang D, Wang B. Chinese woodchucks with different susceptibility to WHV infection differ in their genetic background exemplified by cytochrome B and MHC-DRB molecules. Virol J 2018;15:101. [PMID: 29914514 DOI: 10.1186/s12985-018-1010-y] [Reference Citation Analysis]
225 Ning WF, Wang F, Deng HJ, Chen HH. Screening of differentially expressed genes in chronic hepatitis B patients and prediction of related biological pathways. Shijie Huaren Xiaohua Zazhi 2016; 24(16): 2485-2491 [DOI: 10.11569/wcjd.v24.i16.2485] [Reference Citation Analysis]
226 Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. Int J Mol Sci 2019;20:E2754. [PMID: 31195619 DOI: 10.3390/ijms20112754] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
227 Gu Y, Lian Y, Zheng Q, Huang Z, Gu L, Bi Y, Li J, Huang Y, Wu Y, Chen L, Huang Y. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B. BMC Infect Dis 2020;20:509. [PMID: 32664850 DOI: 10.1186/s12879-020-05233-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
228 Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol 2018;30:24-31. [PMID: 29453099 DOI: 10.1016/j.coviro.2018.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
229 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 18.3] [Reference Citation Analysis]
230 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
231 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
232 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
233 Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020;20:480-490. [PMID: 32278307 DOI: 10.1016/j.omtn.2020.03.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
234 Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
236 Schuch A, Salimi Alizei E, Heim K, Wieland D, Kiraithe MM, Kemming J, Llewellyn-Lacey S, Sogukpinar Ö, Ni Y, Urban S, Zimmermann P, Nassal M, Emmerich F, Price DA, Bengsch B, Luxenburger H, Neumann-Haefelin C, Hofmann M, Thimme R. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 2019;68:905-15. [PMID: 30622109 DOI: 10.1136/gutjnl-2018-316641] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 26.0] [Reference Citation Analysis]
237 Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current Status of Therapy and Future Therapies. Gastroenterol Clin North Am 2020;49:215-38. [PMID: 32389360 DOI: 10.1016/j.gtc.2020.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
238 Hoogeveen RC, Boonstra A. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. Front Immunol 2020;11:401. [PMID: 32194573 DOI: 10.3389/fimmu.2020.00401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
239 Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 2019;68:893-904. [PMID: 30580250 DOI: 10.1136/gutjnl-2018-316644] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 19.0] [Reference Citation Analysis]